AV-101
AV-101 (also known as 4-Cl-KYN or L-4-chlorokynurenine) is a prodrug that is converted in the brain into 7-chlorokynurenic acid (7-Cl-KYNA), an antagonist of the NMDA receptor. It is being developed as a treatment for major depressive disorder and neuropathic pain.
Pharmacology[edit | edit source]
AV-101 is a prodrug of 7-chlorokynurenic acid (7-Cl-KYNA), a potent and selective antagonist of the glycine site of the NMDA receptor. The NMDA receptor is a subtype of glutamate receptor. NMDA receptor antagonists like 7-Cl-KYNA are thought to have potential in the treatment of conditions such as depression, neuropathic pain, and epilepsy, among others.
Clinical trials[edit | edit source]
AV-101 has been studied in Phase 2 clinical trials for the treatment of major depressive disorder and neuropathic pain. The results of these trials have not yet been published.
See also[edit | edit source]
References[edit | edit source]
| AV-101 Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
